Investigation of the correlation of adropin with anthropological and psychological factors in schizophrenia: preliminary evidence from a case-control study

Running title: adropin and anthropological and psychological factors in schizophrenia

Yuko Nishida[1, 2, 4], Ryusei Nishi[1, 4], Takamasa Fukumoto[1], Ei'ichi Iizasa[1], Yoshiaki Nishida[1, 3, 4], and Akihiro Asakawa[*, 1]

[1]Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.

[2]Sanshinkai Nishida Hospital, Ibusuki, Kagoshima, 891-0143, Japan.

[3]Department of Psychiatry, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.

[4]These authors contributed equally to this work.

[*]To whom correspondence should be addressed: Akihiro Asakawa, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. TEL: +81 99 275 5751/FAX: +81 99 275 5749 Email: asakawa@m2.kufm.kagoshima-u.ac.jp

Abstract word counts: 247

Textbody word counts: 2823

Abstract

Background and Hypothesis: Schizophrenia is a disease characterized by various symptoms and has severe lifelong impacts on patients and their families. Despite various hypotheses and associated studies, the key mechanism in schizophrenia is not fully elucidated. In the present study, we focused on adropin, a peptide regulating energy metabolism, antioxidation, and neuroprotection.

Study Design: In both the group of healthy volunteers (HV) and the group of patients with some schizophrenia spectrum and other psychotic disorders (SZ), we evaluated adropin along with other variables such as anthropological factors, psychological well-being indicators, and laboratory test results.

Study Results: The adropin levels in SZ were not significantly different from those in HV. Correlation analysis indicated five significant correlations beyond various natural correlations arising from fundamental proportional relationships and multifaceted psychological well-being indicators: (1) adropin versus right handgrip strength in the SZ group ($\tau = -0.82$, $P = 0.066$); (2) adropin versus selenium in the total group ($\tau = 0.44$, $P = 0.053$); (3) ferritin versus perceived stress in the total group ($\tau = -0.44$, $P = 0.053$); (4) right versus left handgrip strength in the total group ($\tau = 0.70$, $P = 0.001$) and in the SZ group ($\tau = 0.82$, $P = 0.075$); and (5) selenium versus state anxiety

in the total group ($\tau = 0.44$, $P = 0.053$) and the SZ group ($\tau = 0.84$, $P = 0.066$).

Conclusions: The present study provides a foundation for future studies and sheds light on the role of adropin in schizophrenia.

Keywords: Adropin; Schizophrenia; Correlation Analysis; Selenium; Ferritin; Handgrip Strength

Introduction

Schizophrenia, a disease characterized by various symptoms, including positive, negative, and disorganization symptoms,[1] is a severe and complex mental disorder that affects society. Patients with schizophrenia not only suffer from psychiatric symptoms but also from severe functional impairments, which antipsychotics cannot improve.[2] The social and economic burden on family caregivers reduces the quality of life and overwhelms them emotionally.[3] The prevalence has traditionally been estimated at 1 out of 100, which is considered relatively high considering the severity of symptoms and their lifelong impacts. In Japan, the total cost in 2008 was estimated to be 23.8 billion USD,[4] which accounted for approximately 10 percent of the national social security costs.

The main hypothesis of schizophrenia is dysfunction in neurotransmission, and there is substantial evidence for the two main neurotransmitters, dopamine and glutamate.[1] Furthermore, other promising targets have been studied, such as muscarinic receptors (M_1 and M_4) and glycine transporter 1.[5] Despite various hypotheses and associated studies, the key mechanism in schizophrenia is not fully elucidated. Recently, schizophrenia has been studied from the perspective of brain energy metabolism. Antipsychotics such as haloperidol and risperidone impair complex I activity in mitochondria, hindering cellular respiration and thus leading to adenosine triphosphate depletion or increasing reactive oxygen species.[6–8]

Various peptides and neurons are involved in brain metabolism. Recently, a 76-amino acid polypeptide of adropin was identified.[9] Adropin is encoded by the energy homeostasis-associated gene located at chromosome 9p13.3, and is widely expressed, including in the brain. Adropin might play a crucial role in energy metabolism,[10] as evidenced by its activation of the phosphatidylinositol-3 kinase/protein kinase B and extracellular signal-regulated kinase pathway, which is important in cancer,[11] or by protecting endothelial cells through the expression of endothelial nitric oxide synthase, which facilitates nitric oxide production.[12,13]

Considering schizophrenia from the perspectives of energy metabolism and the

role of adropin therein, it might be natural to hypothesize the relationship between adropin and anthropological and psychological factors in schizophrenia. Nevertheless, to the best of our knowledge, no study has focused on adropin in schizophrenia based on human or animal models. If the disease characteristics could be explained through adropin, adropin might be a key target in the treatment of schizophrenia. Therefore, we measured adropin levels in patients with schizophrenia and performed a preliminary study to investigate adropin and the correlation with anthropological and psychological factors of this disease.

Methods

Participants

The study was performed in the Department of Psychosomatic Internal Medicine at Kagoshima University Hospital and Nishida Hospital (Kagoshima, Japan). Written informed consent was obtained from healthy volunteers (HV) and the patients with some schizophrenia spectrum and other psychotic disorders (SZ). We recruited participants using posters. All the participants who completed the experiments received 3,000 Japanese yen as compensation for their participation in the study.

In the schizophrenia spectrum and other psychotic disorders, according to the

Diagnostic and Statistical Manual of Mental Disorders Fifth Edition,[14] participants were required to be diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder. The diagnosis was made by psychiatrists.

In both groups, all participants were required to be between 45 and 65 years old, and participation had to be voluntary. Participants were excluded when psychiatrists assessed that participation in the study was inappropriate due to the severity of their psychotic symptoms.

Study design

This was an observational case-control study aimed to investigate adropin levels and their correlations with various variables. The study protocol was approved by the Institutional Review Board of Kagoshima University Hospital (IRB approval number 230025 and 250090). Before the study, all participants were instructed to fast for 12 hours to obtain accurate laboratory test results. On the study day, in the morning, anthropological measurements (height, weight, and right and left handgrip strength (grip_R and grip_L)) were performed, followed by psychological tests and blood sample collection. Only in SZ, during psychological testing, the psychiatrists assessed the severity of their symptoms, followed by obtaining disease duration and the dosage of antipsychotic drugs converted to chlorpromazine equivalents from medical records.

Psychological assessments

Participants were assessed for their psychological well-being using various questionnaires. First, for the evaluation of subjective depressed moods, anxiety, and trait emotional intelligence, we used the Zung Self-Rating Depression Scale （SDS）,[15] the State-Trait Anxiety Inventory Form X (STAI),[16] which consisted of state and trait anxiety, and the Trait Emotional Intelligence Questionnaire-Short Form (TEIQue_SF),[17] respectively. Second, for subjective sleep quality and perceived stress, the Pittsburgh Sleep Quality Index (PSQI)[18] and the Perceived Stress Scale (PSS)[19] were used, respectively. Finally, for apathy, we used the Japanese version of the Apathy Scale (AS),[20] whose validity has been confirmed.[21]

Psychiatric assessments

In SZ, the symptoms were assessed by psychiatrists using the Positive and Negative Syndrome Scale (PANSS).[22] Briefly, PANSS is composed of 3 main domains: 7 items of positive symptoms, 7 items of negative symptoms, and 16 items of general psychopathology. Each item is scored from 1 to 7, as 1 indicates absence of symptoms and 7 indicates extreme symptoms. Therefore, the symptom severity ranges between 30 and 210.

Laboratory tests

We obtained blood samples, and serum levels of calcium, copper, iron, selenium, zinc, vitamins A and B1, and ferritin were measured by a biochemical testing laboratory (Biken Co., Ltd., Kagoshima, Japan). Additionally, serum adropin levels were measured using ELISA kits of EK-032-35 (Phoenix Pharmaceuticals, USA), according to the manufacturer's instructions.

Software

We conducted the statistical analysis using Python version 3.11.5, pandas version 2.1.1, and Visual Studio Code version 1.97.2. Kendall's correlation coefficient tau was calculated, and multiple comparison corrections with Bonferroni's correction or false discovery rates were applied using statsmodels version 0.14.0. Data were visualized using seaborn version 0.13.2 and matplotlib version 3.8.0.

Statistical analysis

First, we visually analyzed the variables by boxplots and estimated kernel density. Then, we divided the parameters into three domains: (1) anthropological parameters, (2) psychological parameters, and (3) laboratory test parameters. For each domain, assuming that all variables followed nonparametric distribution due to small sample sizes, medians were compared between HV and SZ using the Mann-Whitney U test with Bonferroni's correction.

Third, we calculated Kendall's correlation coefficient tau using multiple comparison corrections via false discovery rate (FDR). Because the aim was to detect potential correlations, the FDR threshold was set at 0.1. Finally, for the difference in tau between HV and SZ, each tau was subjected to an inverse hyperbolic tangent transformation to address boundedness and the difference was evaluated using a normal approximation-based Z-test with multiple comparison corrections via FDR. The FDR threshold was set at 0.05 because the aim was to compare the correlation between groups.

Results

The study was performed from October 17, 2022, to October 2, 2023. A total of 20 participants (HV: 10; SZ: 10) completed the study, and no participants were excluded, though one participant in SZ had a comorbidity of diabetes mellitus with a stabilized blood sugar level. In SZ, all participants were hospitalized. The variables of study participants are summarized in the Supplementary Table.

For the PANSS, we only present general psychopathology scores, because it includes both positive and negative symptoms.[23] PSQI, PSS, and grip_R indicated significant differences between groups. For the adropin levels, estimated kernel density

and boxplots showed no significant differences (Supplementary Table 1; Fig 1). Additionally, paired correlations of all variables, along with their linear regression lines are displayed in the supplementary figure (Supplementary Fig S1).

Kendall's correlation coefficients of tau

When the group was not divided, various significant correlations were observed, and most of them were related to psychological tests and anthropological parameters (Supplementary Fig S2).

In SZ, adropin and grip_R negatively correlated (τ = -0.82, P = 0.066), and selenium and state anxiety in the STAI (STAI_S) positively correlated (τ = 0.84, P = 0.066) (Fig 2). On the other hand, in the HV, only the positive correlation between grip_R and grip_L (τ = 0.82, P = 0.075) was indicated as significant (Fig 3).

Differences in correlation coefficients for each variable are displayed in Fig 4. A significant negative difference was observed only in the correlation between adropin and grip_R (difference of τ = -0.98, P = 0.013). Significant findings in the further discussions are summarized in Table 1.

Table 1. Significant correlations found in the analysis of Kendall's correlations and their differences.

Correlations		Total (τ, P)	HV (τ, P)	SZ (τ, P)	Difference (τ_{diff}, P)
Adropin	Grip_R	τ = -0.14, P = 0.720	τ = 0.16, P = 0.937	**τ = -0.82, P = 0.066**	**τ_{diff} = -0.98, P = 0.013**

	Selenium	**τ = 0.44, *P* = 0.053**	τ = 0.58, *P* = 0.394	τ = 0.30, *P* = 0.651	τ_{diff} = -0.29, *P* = 0.495
Ferritin	PSS	**τ = -0.44, *P* = 0.053**	τ = -0.33, *P* = 0.811	τ = -0.49, *P* = 0.311	τ_{diff} = -0.16, *P* = 0.720
Grip_L	Grip_R	**τ = 0.70, *P* = 0.001**	**τ = 0.82, *P* = 0.075**	τ = 0.64, *P* = 0.137	τ_{diff} = -0.18, *P* = 0.457
Selenium	STAI_S	**τ = 0.44, *P* = 0.053**	τ = 0.40, *P* = 0.689	**τ = 0.84, *P* = 0.066**	τ_{diff} = 0.44, *P* = 0.136

The false discovery rate threshold was set at 0.05 in the correlation analysis and was set at 0.10 in the difference of correlations.

AS = Apathy Scale, HV = healthy volunteers, PSS = Perceived Stress Scale, STAI = State-Trait Anxiety Inventory Form X, STAI_S = state anxiety in STAI, SZ = the group of patients with some schizophrenia spectrum and other psychotic disorders, τ_{diff} = the difference of τ calculated as the subtraction of tau in HV from SZ.

Discussion

Adropin levels in SZ are the same as in HV

The adropin levels are consistent with previous studies that measured adropin using the same ELISA kits,[24–27] suggesting that the measurement was accurate and reliable. The levels were not significantly different between HV and SZ. Therefore, schizophrenia may not alter adropin levels.

Interpretation of Kendall's correlation test analyses

When the study group was not divided, the intergroup association in psychological tests was natural because psychological well-being involves various overlapping factors, such as anxiety, depressed moods, emotional intelligence, perceived stress, sleep quality, and vigor, which have intricate relationships. The

intergroup association in anthropological parameters was also natural, reflecting fundamental proportional relationships in human morphology.

However, most of the associations were not detected when the group was divided. Although one possible reason is the reduced statistical power due to small sample size, the variables' distributions might indicate another source of statistical bias, known as range restriction.[28]

In our study, psychological test scores, especially PSQI and PSS, were distributed differently between groups (Fig 1). On the contrary, laboratory tests, especially vitamins, selenium, and zinc, were distributed similarly. In anthropological parameters, handgrip strength and weight were distributed differently, but age and height were distributed relatively similarly. Thus, the difference in distributions may suggest that range restriction has influenced the detectability of associations. Based on these considerations, the correlation between selenium and adropin or STAI_S and ferritin and PSS might be important findings.

Statistical interpretations of significant correlations

As displayed in Table 1, significant correlations (i.e., correlations that showed statistical significance in the total group, in either group, or in the group difference, but were not attributed to natural or fundamental relationships) could be divided into three

types: (1) not significant in the total group but significant in either SZ or HV, and the difference was statistically significant (adropin and grip_R), (2) not significant in both SZ and HV, with a non-statistically significant group difference, but significant in the total group (adropin and selenium, and ferritin and PSS), and (3) significant in the total group and either SZ or HV, but the difference is not significant (selenium and STAI_S, and grip_R and grip_L).

In the first type of correlation, a significant difference between groups was observed, and the significance was indicated in either group, which might reflect a real effect modulated by a group factor. In the second type of correlation, the non-detection of the correlation between ferritin and PSS in each group might be attributed to range restriction, considering the discrepant distributions of PSS in their boxplots (Fig 1). On the other hand, the distributions of adropin and selenium were similar across groups, suggesting that the lack of significance in each group may be due to insufficient statistical power rather than range restriction. Finally, in the third type of correlation, the observed correlation pattern of grip_R and grip_L differed from that of selenium and STAI_S. First, the correlation between grip_R and grip_L was relatively high in both groups, and the correlation in the total group was also relatively high. However, given that the scatter plot follows an approximately linear trend, as confirmed by the linear

regression (Supplementary Figure), the non-detection of the correlation in SZ might be attributed to insufficient statistical power. Second, the correlation between selenium and STAI_S was high in SZ, but only significant in HV. Moreover, the scatter plot follows an approximately linear trend in SZ (Supplementary Figure). Therefore, the detected correlation in the total group might primarily reflect the strong correlation in SZ.

Psychophysiological implications of the findings

Herein, we discuss the observed significant correlations from psychophysiological aspects, assuming the statistical validity discussed in the previous section.

Correlation between the right and left handgrip strength

The correlation between grip_R and grip_L is natural, but the correlation was not detected in SZ. In SZ, handgrip strength is lower than HV, aligning with previous research.[29,30] Although the correlation between the right and left hand is not indicated in previous research, it can be inferred that the decrease in handgrip strength in both hands weakened the fundamental correlation observed in HV.

Correlation between the perceived stress and ferritin levels

The correlation between ferritin and PSS may suggest that perceived stress reduces stored iron or that reduced stored iron is associated with higher stress. Findings

such as decreased intestinal ferritin absorption in rodents[31] and lower ferritin levels in patients with coronavirus disease in intensive care units with psychiatric comorbidity[32] align with our finding. Although the detected negative correlation between ferritin and PSS seems plausible based on the previous research, it should be noted that ferritin level is generally discussed in terms of iron deficiency.

Correlation between selenium and state anxiety

The positive correlation between selenium and state anxiety in SZ may suggest that selenium elevates anxiety levels in a state or that elevated selenium levels might be associated with a temporary high level of anxiety. The mechanism of selenium in the brain includes antioxidative effects induced by selenoproteins,[33,34] neurotransmission,[35–37] and neuroprotection.[38]

An association of low levels of selenium with schizophrenia has been reported,[39,40] and the improvement of the schizophrenic symptoms by the co-supplementation of selenium and probiotics[41] is consistent with the findings. In contrast, a meta-analysis indicated no significant associations of selenium levels with schizophrenia.[42]

In the present study, the correlation between state anxiety and selenium in SZ was not negative but positive. The normal selenium levels differ greatly between studies

and countries,[43,44] and a recent Japanese government study reported that the mean Japanese blood selenium levels were 180 μg/L.[45] Therefore, the mean levels of 144.0 in HV can be considered as normal. However, assuming an optimal selenium range of around 80μg/L regarding anxiety or depression,[46,47] adverse effects of selenium including transient anxiety[48] might be plausible for the observed correlation in the present study.

Correlation between adropin and selenium

The role of adropin in the central nervous system is extensively described by Shahjouei et al., focusing on the signaling pathways.[49] In schizophrenia, briefly, Akt/GSK3β pathway, which is the phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) through the signaling molecule of Akt, is considered a key mechanism of antipsychotics targeting dopamine D2 receptors.[50] Interestingly, the downregulation of GSK3β is reported in the condition of selenium deficiency.[51] Moreover, adropin mediates the redox signaling through various pathways[52] and selenium is a key factor in these pathways.[53] Therefore, the association of adropin with selenium through GSK3β regulation and redox signaling appears plausible.

Correlation between adropin and handgrip strength in schizophrenia

The association of adropin with grip_R may reflect a real effect modulated by a

group factor, according to the previous statistical discussion. Herein we discuss from the perspectives of (1) neural recognition molecule-3 (NB-3)/Notch 1 signaling pathways and (2) interaction with dopamine. First, in rodents, adropin-knockout mice decreased locomotor activities and ambulatory movements, which is attributed to the NB3/Notch1 signaling pathways[54] functioning in both the developmental and post-developmental stages.[55] However, the neuromuscular mechanism has not been focused, suggesting that the NB3/Notch 1 pathway's contribution to the handgrip strength is inconclusive.

Second, an interaction between adropin and D2 receptors might be inferred since a potential adropin receptor G-protein coupled receptor 19 (GPR19)[56] has a similar structure to the dopamine D2 receptors.[57] In schizophrenia, a key mechanism is nigrostriatal pathways rather than mesolimbic pathways,[59] patients exhibit overexpression of striatum D2 receptors, antipsychotics inhibit dopamine release, and the chronic antipsychotic treatment downregulates dopamine synthesis in some patients.[60,61] Therefore, the comparable adropin levels in SZ to those of HV might be plausible if antipsychotics downregulated dopamine synthesis. On the other hand, if the dopamine levels were not comparable in SZ to those in HV, it can be hypothesized that adropin might be modulated by negative feedback for D2 dysregulation. Last but not least, these discussions should be carefully interpreted because we could not evaluate

dopamine levels in the present study.

Limitations

First, statistical results should be carefully interpreted by considering the small sample size, since this was a preliminary study and the main objective was to present the potential role of adropin in schizophrenia. However, we have discussed results carefully and consistently by considering the sample size shortage. Second, it should be noted that all participants in SZ were hospitalized. The hospital environment may introduce bias in handgrip strength or psychological well-being, but the patients performed physical activities and were not confined to bed. Third, because this was a preliminary study performed in men, the results should not apply to women. Last, the exclusion criteria did not include comorbidities. One participant in SZ had diabetes mellitus, which has extensively suggested the strong association between schizophrenia[62] and adropin.[63]

Conclusion

Upon considering the limitations, to the best of our knowledge, we first provide preliminary evidence of the association of adropin with schizophrenia. The present study provides a foundation for future studies and sheds light on adropin in

schizophrenia, which might be a potential therapeutic target in schizophrenia.

Abbreviations

D2: dopamine D2 receptor

FDR: false discovery rate

GPR19: G-protein coupled receptor 19

grip_L: left handgrip strength

grip_R: right handgrip strength

GSK3β: glycogen synthase kinase 3β

HV: the group of healthy volunteers

NB-3: neural recognition molecule-3

PANSS: Positive and Negative Syndrome Scale

PSQI: Pittsburgh Sleep Quality Index

PSS: Perceived Stress Scale

STAI: State-Trait Anxiety Inventory Form X

STAI_S: state anxiety in STAI

SZ: the group of patients with some schizophrenia spectrum and other psychotic disorders

Conflicts of Interest

The Authors have declared that there are no conflicts of interest in relation to the subject of this study.

Funding

This study was not supported by any sponsor or funder.

Acknowledgements

We acknowledge the support of Dr. Haruki Iwai for his comments on the study results, and Dr. Kenichiro Sagiyama for his technical assistance.

References

1. Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. *The Lancet*. 2022;399(10323):473-486. doi:10.1016/S0140-6736(21)01730-X

2. Raj V, Stogios N, Agarwal SM, Cheng AJ. The neuromuscular basis of functional impairment in schizophrenia: A scoping review. *Schizophrenia Research*. 2024;274:46-56. doi:10.1016/j.schres.2024.09.002

3. Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers: a review. *Pharmacoeconomics*. 2008;26(2):149-162. doi:10.2165/00019053-200826020-00005

4. Sado M, Inagaki A, Koreki A, et al. The cost of schizophrenia in Japan. *Neuropsychiatric Disease and Treatment*. 2013;9:787-798. doi:10.2147/NDT.S41632

5. Dudzik P, Lustyk K, Pytka K. Beyond dopamine: Novel strategies for schizophrenia

treatment. *Medicinal Research Reviews*. 2024;44(5):2307-2330. doi:10.1002/med.22042

6. Kolar D, Kleteckova L, Brozka H, Vales K. Mini-review: Brain energy metabolism and its role in animal models of depression, bipolar disorder, schizophrenia and autism. *Neuroscience Letters*. 2021;760. doi:10.1016/j.neulet.2021.136003

7. Pruett BS, Meador-Woodruff JH. Evidence for altered energy metabolism, increased lactate, and decreased pH in schizophrenia brain: A focused review and meta-analysis of human postmortem and magnetic resonance spectroscopy studies. *Schizophrenia Research*. 2020;223:29-42. doi:10.1016/j.schres.2020.09.003

8. Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M. Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. *Neuroscience and Biobehavioral Reviews*. 2015;48:10-21. doi:10.1016/j.neubiorev.2014.11.005

9. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. *Cell Metab*. 2008;8(6):468-481. doi:10.1016/j.cmet.2008.10.011

10. Chen L, Lu J, Hu J, Gong X. Unveiling the multifaceted role of adropin in various diseases (Review). *International Journal of Molecular Medicine*. 2024;54(4). doi:10.3892/ijmm.2024.5414

11. Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. *Annu Rev Med*. 2016;67:11-28. doi:10.1146/annurev-med-062913-051343

12. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. *Circulation*. 2010;122(11 Suppl):S185-192. doi:10.1161/CIRCULATIONAHA.109.931782

13. Li B, Wang Z, He Y, et al. Adropin Improves Radiation-Induced Myocardial Injury via VEGFR2/PI3K/Akt Pathway. *Oxid Med Cell Longev*. 2022;2022:8230214. doi:10.1155/2022/8230214

14. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5.* 5th edition. Arlington, VA: American Psychiatric Association; 2013.

15. Zung WWK, Richards CB, Short MJ. Self-Rating Depression Scale in an Outpatient Clinic: Further Validation of the SDS. *Arch Gen Psychiatry*. 1965;13(6):508-515.

doi:10.1001/archpsyc.1965.01730060026004

16. Iwamoto M, Dodo H, Yoneda J, et al. A study of the State-Trait Anxiety Inventory (STAI) and its application to noise stress. *Japanese Journal of Hygiene*. 1989;43(6):1116-1123. doi:10.1265/jjh.43.1116

17. Siegling AB, Vesely AK, Petrides KV, Saklofske DH. Incremental Validity of the Trait Emotional Intelligence Questionnaire-Short Form (TEIQue-SF). *Journal of Personality Assessment*. 2015;97(5):525-535. doi:10.1080/00223891.2015.1013219

18. Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry research*. 1989;28(2):193-213.

19. Cohen S, Kamarck T, Mermelstein R. A Global Measure of Perceived Stress. *Journal of Health and Social Behavior*. 1983;24(4):385-396. doi:10.2307/2136404

20. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. *J Neuropsychiatry Clin Neurosci*. 1992;4(2):134-139. doi:10.1176/jnp.4.2.134

21. Kawagoe T, Onoda K, Yamaguchi S, Radakovic R. Developing and validating the Japanese version of Dimensional Apathy Scale (J-DAS). *Psychiatry and Clinical Neurosciences*. 2020;74(7):411-412. doi:10.1111/pcn.13009

22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261

23. *Clinical Review Report: Brexpiprazole (Rexulti): (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.): Indication: Treatment of Schizophrenia in Adults*. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017. http://www.ncbi.nlm.nih.gov/books/NBK535498/. Accessed March 21, 2025.

24. Li N, Xie G, Zhou B, et al. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease. *Front Physiol*. 2021;12:696163. doi:10.3389/fphys.2021.696163

25. Wang Q, An Y, Zhang L, Zhang Y, Wang G, Liu J. Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes. *BMC Endocr*

Disord. 2022;22(1):306. doi:10.1186/s12902-022-01233-x

26. Aggarwal G, Morley JE, Vellas B, Nguyen AD, Butler AA, MAPT/DSA Group. Low circulating adropin concentrations predict increased risk of cognitive decline in community-dwelling older adults. *Geroscience*. 2024;46(1):897-911. doi:10.1007/s11357-023-00824-3

27. Aydin S, Eren MN, Yilmaz M, et al. Adropin as a potential marker of enzyme-positive acute coronary syndrome. *Cardiovasc J Afr*. 2017;28(1):40-47. doi:10.5830/CVJA-2016-055

28. Dahlke JA, Wiernik BM. Not Restricted to Selection Research: Accounting for Indirect Range Restriction in Organizational Research. *Organizational Research Methods*. 2020;23(4):717-749. doi:10.1177/1094428119859398

29. Firth J, Stubbs B, Vancampfort D, et al. Grip Strength Is Associated with Cognitive Performance in Schizophrenia and the General Population: A UK Biobank Study of 476559 Participants. *Schizophrenia Bulletin*. 2018;44(4):728-736. doi:10.1093/schbul/sby034

30. Hidese S, Matsuo J, Ishida I, et al. Relationship of handgrip strength and body mass index with cognitive function in patients with schizophrenia. *Frontiers in Psychiatry*. 2018;9(APR). doi:10.3389/fpsyt.2018.00156

31. Wei C, Zhou J, Huang X, Li M. Effects of psychological stress on serum iron and erythropoiesis. *Int J Hematol*. 2008;88(1):52-56. doi:10.1007/s12185-008-0105-4

32. Abulseoud OA, Yehia A, Egol CJ, et al. Attenuated initial serum ferritin concentration in critically ill coronavirus disease 2019 geriatric patients with comorbid psychiatric conditions. *Frontiers in Psychiatry*. 2022;13. doi:10.3389/fpsyt.2022.1035986

33. Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. *Science*. 2003;300(5624):1439-1443. doi:10.1126/science.1083516

34. Rayman MP. Selenium and human health. *Lancet*. 2012;379(9822):1256-1268. doi:10.1016/S0140-6736(11)61452-9

35. Solovyev ND. Importance of selenium and selenoprotein for brain function: From antioxidant protection to neuronal signalling. *J Inorg Biochem*. 2015;153:1-12. doi:10.1016/j.jinorgbio.2015.09.003

36. Reis AS, Pinz M, Duarte LFB, et al. 4-phenylselenyl-7-chloroquinoline, a novel multitarget compound with anxiolytic activity: Contribution of the glutamatergic system. *J Psychiatr Res*. 2017;84:191-199. doi:10.1016/j.jpsychires.2016.10.007

37. Paltian JJ, Dos Reis AS, de Oliveira RL, et al. The anxiolytic effect of a promising quinoline containing selenium with the contribution of the serotonergic and GABAergic pathways: Modulation of parameters associated with anxiety in mice. *Behav Brain Res*. 2020;393:112797. doi:10.1016/j.bbr.2020.112797

38. Baj J, Forma A, Sitarz E, et al. Beyond the Mind-Serum Trace Element Levels in Schizophrenic Patients: A Systematic Review. *Int J Mol Sci*. 2020;21(24):9566. doi:10.3390/ijms21249566

39. Liu T, Lu QB, Yan L, et al. Comparative Study on Serum Levels of 10 Trace Elements in Schizophrenia. *PLOS ONE*. 2015;10(7):e0133622. doi:10.1371/journal.pone.0133622

40. Brown JS. Role of selenium and other trace elements in the geography of schizophrenia. *Schizophr Bull*. 1994;20(2):387-398. doi:10.1093/schbul/20.2.387

41. Jamilian H, Ghaderi A. The Effects of Probiotic and Selenium Co-supplementation on Clinical and Metabolic Scales in Chronic Schizophrenia: a Randomized, Double-blind, Placebo-Controlled Trial. *Biological Trace Element Research*. 2021;199(12):4430-4438. doi:10.1007/s12011-020-02572-3

42. Saghazadeh A, Mahmoudi M, Shahrokhi S, et al. Trace elements in schizophrenia: a systematic review and meta-analysis of 39 studies (N= 5151 participants). *Nutrition reviews*. 2020;78(4):278-303.

43. Navarro-Alarcon M, Cabrera-Vique C. Selenium in food and the human body: A review. *Science of the Total Environment*. 2008;400(1-3):115-141. doi:10.1016/j.scitotenv.2008.06.024

44. Safaralizadeh R, Kardar G, Pourpak Z, Moin M, Zare A, Teimourian S. Serum concentration of Selenium in healthy individuals living in Tehran. *Nutrition Journal*. 2005;4(1):32. doi:10.1186/1475-2891-4-32

45. Environmental Risk Assessment Office Environmental Health Department Ministry of the Environment, Japan. The exposure to chemical compounds in the Japanese

people」: survey of the exposure to chemical compounds in human (2018-). 2024. https://dl.ndl.go.jp/pid/13970475.

46. Sajjadi SS, Foshati S, Haddadian-Khouzani S, Rouhani MH. The role of selenium in depression: a systematic review and meta-analysis of human observational and interventional studies. *Sci Rep*. 2022;12(1):1045. doi:10.1038/s41598-022-05078-1

47. Conner TS, Richardson AC, Miller JC. Optimal serum selenium concentrations are associated with lower depressive symptoms and negative mood among young adults. *J Nutr*. 2015;145(1):59-65. doi:10.3945/jn.114.198010

48. Wu Y, Pei J, Xu Y, Yu F, Xu S. Selenium: 48-year journey of global clinical trials. *Molecular and Cellular Biochemistry*. January 2025. doi:10.1007/s11010-024-05202-x

49. Shahjouei S, Ansari S, Pourmotabbed T, Zand R. Potential roles of adropin in central nervous system: Review of current literature. *Frontiers in Molecular Biosciences*. 2016;3(JUN). doi:10.3389/fmolb.2016.00025

50. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. *Annu Rev Pharmacol Toxicol*. 2009;49:327-347. doi:10.1146/annurev.pharmtox.011008.145634

51. Müller M, Banning A, Brigelius-Flohé R, Kipp A. Nrf2 target genes are induced under marginal selenium-deficiency. *Genes and Nutrition*. 2010;5(4):297-307. doi:10.1007/s12263-010-0168-8

52. Chen X, Xue H, Fang W, et al. Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. *Redox Biology*. 2019;21. doi:10.1016/j.redox.2018.101068

53. Handy DE, Loscalzo J. The role of glutathione peroxidase-1 in health and disease. *Free Radical Biology and Medicine*. 2022;188:146-161. doi:10.1016/j.freeradbiomed.2022.06.004

54. Wong CM, Wang Y, Lee JTH, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. *J Biol Chem*. 2014;289(37):25976-25986. doi:10.1074/jbc.M114.576058

55. Gunraj RE, Yang C, Liu L, Larochelle J, Candelario-Jalil E. Protective roles of adropin in neurological disease. *American Journal of Physiology - Cell Physiology*.

2023;324(3):C674-C678. doi:10.1152/ajpcell.00318.2022

56. Stein LM, Yosten GLC, Samson WK. Adropin acts in brain to inhibit water drinking: Potential interaction with the orphan G protein-coupled receptor, GPR19. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*. 2016;310(6):R476-R480. doi:10.1152/ajpregu.00511.2015

57. Wang J, Chitsaz F, Derbyshire MK, et al. The conserved domain database in 2023. *Nucleic Acids Res*. 2023;51(D1):D384-D388. doi:10.1093/nar/gkac1096

58. Abo El Gheit RE, Atef MM, El Deeb OS, et al. Unique novel role of adropin in a gastric ulcer in a rotenone-induced rat model of Parkinson's disease. *ACS Chemical Neuroscience*. 2020;11(19):3077-3088. doi:10.1021/acschemneuro.0c00424

59. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. *Trends in Neurosciences*. 2019;42(3):205-220. doi:10.1016/j.tins.2018.12.004

60. McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: A meta-analysis and test of the mesolimbic hypothesis. *Schizophrenia Bulletin*. 2018;44(6):1301-1311. doi:10.1093/schbul/sbx180

61. Gründer G, Vernaleken I, Müller MJ, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. *Neuropsychopharmacology*. 2003;28(4):787-794. doi:10.1038/sj.npp.1300103

62. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. *Acta Psychiatrica Scandinavica*. 2015;132(2):144-157. doi:10.1111/acps.12439

63. Zhang H, Chen N. Adropin as an indicator of T2DM and its complications. *Food Science and Human Wellness*. 2022;11(6):1455-1463. doi:10.1016/j.fshw.2022.06.002

Figure Legends

Figure 1. Estimated kernel densities and boxplots of the variables.

AS = Apathy Scale, Ca = calcium, Cu = copper, Fe = iron, HV = the group of healthy volunteers, PANSS = Positive and Negative Syndrome Scale, PSQI = Pittsburgh Sleep Quality Index, PSS = Perceived Stress Scale, SDS = Zung Self-Rating Depression Scale, Se = selenium, STAI = State-Trait Anxiety Inventory Form X, STAI_S = state anxiety in STAI, STAI_T = trait anxiety in STAI, SZ = the group of patients with some schizophrenia spectrum and other psychotic disorders, TEIQue_SF = Trait Emotional Intelligence Questionnaire Short Form, Zn = zinc.

Figure 2. Correlation coefficients in participants with schizophrenia.

AS = Apathy Scale, Ca = calcium, Cu = copper, Fe = iron, HV = the group of healthy volunteers, PANSS = Positive and Negative Syndrome Scale, PSQI = Pittsburgh Sleep Quality Index, PSS = Perceived Stress Scale, SDS = Zung Self-Rating Depression Scale, Se = selenium, STAI = State-Trait Anxiety Inventory Form X, STAI_S = state anxiety in STAI, STAI_T = trait anxiety in STAI, SZ = the group of patients with some schizophrenia spectrum and other psychotic disorders, TEIQue_SF = Trait Emotional Intelligence Questionnaire Short Form, Zn = zinc.

Figure 3. Correlation coefficients in healthy volunteer participants.

AS = Apathy Scale, Ca = calcium, Cu = copper, Fe = iron, HV = the group of healthy volunteers, PANSS = Positive and Negative Syndrome Scale, PSQI = Pittsburgh Sleep Quality Index, PSS = Perceived Stress Scale, SDS = Zung Self-Rating Depression Scale, Se = selenium, STAI = State-Trait Anxiety Inventory Form X, STAI_S = state anxiety in STAI, STAI_T = trait anxiety in STAI, SZ = the group of patients with some schizophrenia spectrum and other psychotic disorders, TEIQue_SF = Trait Emotional Intelligence Questionnaire Short Form, Zn = zinc.

Figure 4. Correlation coefficients difference between groups.

AS = Apathy Scale, Ca = calcium, Cu = copper, Fe = iron, HV = the group of healthy volunteers, PANSS = Positive and Negative Syndrome Scale, PSQI = Pittsburgh Sleep Quality Index, PSS = Perceived Stress Scale, SDS = Zung Self-Rating Depression Scale, Se = selenium, STAI = State-Trait Anxiety Inventory Form X, STAI_S = state anxiety in STAI, STAI_T = trait anxiety in STAI, SZ = the group of patients with some schizophrenia spectrum and other psychotic disorders, TEIQue_SF = Trait Emotional Intelligence Questionnaire Short Form, Zn = zinc.


Schizophrenia
Healthy Volunteers
Age
Height
Weight
grip_R
grip_L
AS
SDS
STAI_S
STAI_T
PSQI
PSS
TEIQue_SF
Adropin
A
B1
Ca
Cu
Fe
Ferritin
Se
Zn
Density
SZ
HV

	Age	Height	Weight	grip_R	grip_L	AS	SDS	STAI_S	STAI_T	PSQI	PSS	TEIQue_SF	Adropin	A	B1	Ca	Cu	Fe	Ferritin	Se	Zn
Age																					
Height	−0.28 P = 0.651																				
Weight	−0.34 P = 0.521	0.67 P = 0.137																			
grip_R	−0.11 P = 0.909	0.13 P = 0.882	0.11 P = 0.909										−0.82 P = 0.066								
grip_L	−0.02 P = 0.970	−0.13 P = 0.882	−0.07 P = 0.909	0.64 P = 0.137																	
AS	0.07 P = 0.909	−0.22 P = 0.708	−0.38 P = 0.481	−0.38 P = 0.481	−0.11 P = 0.909																
SDS	0.14 P = 0.882	−0.25 P = 0.675	−0.49 P = 0.289	−0.36 P = 0.481	0.00 P = 1.000	0.54 P = 0.211															
STAI_S	0.43 P = 0.364	−0.22 P = 0.708	−0.56 P = 0.211	−0.29 P = 0.651	−0.20 P = 0.827	0.64 P = 0.137	0.63 P = 0.156		0.78 P = 0.066											0.84 P = 0.066	
STAI_T	0.30 P = 0.651	−0.27 P = 0.651	−0.51 P = 0.289	−0.51 P = 0.289	−0.24 P = 0.708	0.60 P = 0.175	0.76 P = 0.119	0.78 P = 0.066													
PSQI	0.38 P = 0.481	−0.12 P = 0.909	−0.32 P = 0.590	−0.28 P = 0.651	−0.09 P = 0.909	0.46 P = 0.339	0.58 P = 0.202	0.55 P = 0.211	0.69 P = 0.137												
PSS	0.07 P = 0.909	−0.47 P = 0.339	−0.63 P = 0.171	0.16 P = 0.853	0.30 P = 0.651	0.44 P = 0.364	0.33 P = 0.584	0.44 P = 0.364	0.35 P = 0.518	0.27 P = 0.675											
TEIQue_SF	−0.28 P = 0.651	0.25 P = 0.675	0.36 P = 0.481	0.40 P = 0.399	0.22 P = 0.708	−0.72 P = 0.122	−0.61 P = 0.174	−0.72 P = 0.122	−0.58 P = 0.179	−0.44 P = 0.364	−0.38 P = 0.481										
Adropin	0.25 P = 0.675	−0.22 P = 0.708	−0.20 P = 0.827	−0.82 P = 0.066	−0.56 P = 0.211	0.47 P = 0.339	0.45 P = 0.339	0.38 P = 0.481	0.60 P = 0.175	0.46 P = 0.339	−0.07 P = 0.909	−0.49 P = 0.289									
A	0.07 P = 0.909	0.40 P = 0.399	0.20 P = 0.827	−0.07 P = 0.909	−0.07 P = 0.909	0.24 P = 0.708	−0.04 P = 0.909	0.24 P = 0.708	0.11 P = 0.909	0.23 P = 0.708	−0.16 P = 0.853	−0.22 P = 0.708	−0.02 P = 1.000								
B1	−0.30 P = 0.651	0.54 P = 0.211	0.29 P = 0.651	0.20 P = 0.827	0.11 P = 0.909	−0.29 P = 0.651	−0.09 P = 0.909	−0.29 P = 0.651	−0.16 P = 0.882	−0.23 P = 0.708	−0.16 P = 0.853	0.40 P = 0.399	−0.29 P = 0.651	0.11 P = 0.909							
Ca	0.05 P = 0.909	0.49 P = 0.311	0.41 P = 0.399	−0.28 P = 0.651	−0.28 P = 0.651	0.09 P = 0.909	−0.21 P = 0.755	0.05 P = 0.909	−0.05 P = 0.909	−0.07 P = 0.909	−0.39 P = 0.481	−0.16 P = 0.853	0.09 P = 0.909	0.69 P = 0.137	0.05 P = 0.909						
Cu	−0.25 P = 0.675	−0.04 P = 0.909	0.11 P = 0.909	0.11 P = 0.909	0.29 P = 0.651	0.07 P = 0.909	0.09 P = 0.909	−0.02 P = 1.000	−0.16 P = 0.882	−0.23 P = 0.708	−0.07 P = 0.909	−0.13 P = 0.882	−0.11 P = 0.909	−0.07 P = 0.909	−0.16 P = 0.882	0.00 P = 1.000					
Fe	−0.28 P = 0.651	0.16 P = 0.853	−0.09 P = 0.909	−0.04 P = 0.909	−0.04 P = 0.909	−0.04 P = 0.909	0.20 P = 0.755	−0.09 P = 0.909	0.13 P = 0.882	0.07 P = 0.909	0.24 P = 0.708	0.16 P = 0.853	−0.04 P = 0.909	−0.27 P = 0.651	0.63 P = 0.156	−0.35 P = 0.518	−0.27 P = 0.651				
Ferritin	−0.07 P = 0.909	0.27 P = 0.651	0.42 P = 0.399	−0.20 P = 0.827	−0.11 P = 0.909	0.11 P = 0.909	−0.27 P = 0.651	−0.16 P = 0.882	−0.11 P = 0.909	−0.09 P = 0.909	−0.49 P = 0.311	0.04 P = 0.909	0.11 P = 0.909	0.42 P = 0.399	−0.11 P = 0.909	0.60 P = 0.177	0.24 P = 0.708	−0.40 P = 0.399			
Se	0.26 P = 0.675	−0.18 P = 0.827	−0.43 P = 0.364	−0.20 P = 0.755	−0.16 P = 0.853	0.66 P = 0.137	0.55 P = 0.211	0.84 P = 0.066	0.66 P = 0.137	0.61 P = 0.177	0.50 P = 0.311	−0.74 P = 0.122	0.30 P = 0.651	0.39 P = 0.446	−0.39 P = 0.446	0.14 P = 0.882	−0.07 P = 0.909	−0.14 P = 0.882	−0.11 P = 0.909		
Zn	0.07 P = 0.909	0.04 P = 0.909	0.07 P = 0.909	−0.47 P = 0.339	−0.56 P = 0.211	0.02 P = 1.000	−0.18 P = 0.827	0.02 P = 1.000	0.07 P = 0.909	0.00 P = 1.000	−0.07 P = 0.909	−0.04 P = 0.909	0.38 P = 0.481	−0.11 P = 0.909	−0.02 P = 1.000	0.14 P = 0.882	−0.47 P = 0.339	0.13 P = 0.882	0.02 P = 1.000	−0.02 P = 0.970	



	Age	Height	Weight	grip_R	grip_L	AS	SDS	STAI_S	STAI_T	PSQI	PSS	TEIQue_SF	Adropin	A	B1	Ca	Cu	Fe	Ferritin	Se	Zn
Age																					
Height	−0.28 P = 0.849																				
Weight	0.11 P = 0.937	0.49 P = 0.533																			
grip_R	0.16 P = 0.937	0.09 P = 0.937	0.38 P = 0.743		0.82 P = 0.075																
grip_L	0.07 P = 0.966	0.00 P = 1.000	0.29 P = 0.849	0.82 P = 0.075																	
AS	0.00 P = 1.000	−0.30 P = 0.849	−0.18 P = 0.937	−0.04 P = 0.978	0.13 P = 0.937																
SDS	−0.02 P = 0.994	−0.51 P = 0.533	−0.39 P = 0.731	−0.34 P = 0.787	−0.16 P = 0.937	0.74 P = 0.158															
STAI_S	−0.02 P = 0.994	−0.27 P = 0.849	−0.07 P = 0.978	−0.16 P = 0.937	0.02 P = 1.000	0.40 P = 0.689	0.43 P = 0.689														
STAI_T	0.09 P = 0.937	−0.35 P = 0.787	−0.09 P = 0.937	0.00 P = 1.000	0.18 P = 0.937	0.72 P = 0.169	0.71 P = 0.186	0.41 P = 0.689													
PSQI	0.02 P = 0.994	0.02 P = 0.994	0.09 P = 0.937	0.28 P = 0.849	0.38 P = 0.736	0.41 P = 0.731	0.14 P = 0.937	0.38 P = 0.736	0.27 P = 0.887												
PSS	−0.10 P = 0.937	−0.50 P = 0.557	−0.42 P = 0.689	0.09 P = 0.937	0.19 P = 0.937	0.45 P = 0.689	0.58 P = 0.417	0.14 P = 0.937	0.61 P = 0.394	0.15 P = 0.937											
TEIQue_SF	0.16 P = 0.937	0.31 P = 0.811	0.11 P = 0.937	0.11 P = 0.937	−0.07 P = 0.978	−0.76 P = 0.154	−0.75 P = 0.154	−0.60 P = 0.394	−0.78 P = 0.154	−0.38 P = 0.736	−0.57 P = 0.417										
Adropin	0.07 P = 0.966	0.13 P = 0.937	0.51 P = 0.533	0.16 P = 0.937	0.16 P = 0.937	0.22 P = 0.934	0.02 P = 0.994	0.33 P = 0.811	0.28 P = 0.849	0.14 P = 0.937	−0.09 P = 0.937	−0.29 P = 0.849									
A	−0.02 P = 0.994	−0.27 P = 0.849	−0.16 P = 0.937	0.11 P = 0.937	0.11 P = 0.937	−0.04 P = 0.978	−0.07 P = 0.966	0.29 P = 0.849	−0.14 P = 0.937	0.09 P = 0.937	−0.19 P = 0.937	0.02 P = 1.000	0.07 P = 0.978								
B1	−0.02 P = 0.994	0.18 P = 0.937	0.24 P = 0.937	−0.11 P = 0.937	−0.02 P = 1.000	−0.18 P = 0.937	−0.25 P = 0.888	0.07 P = 0.978	−0.23 P = 0.934	−0.28 P = 0.849	−0.61 P = 0.394	0.33 P = 0.811	0.11 P = 0.937	0.33 P = 0.811							
Ca	0.21 P = 0.937	0.32 P = 0.811	0.52 P = 0.500	0.57 P = 0.417	0.48 P = 0.557	−0.09 P = 0.937	−0.35 P = 0.787	0.07 P = 0.966	−0.05 P = 0.978	0.14 P = 0.937	−0.19 P = 0.937	0.07 P = 0.966	0.43 P = 0.689	−0.02 P = 0.994	0.11 P = 0.937						
Cu	0.00 P = 1.000	0.07 P = 0.966	0.13 P = 0.937	0.27 P = 0.849	0.27 P = 0.849	0.32 P = 0.811	0.05 P = 0.978	−0.09 P = 0.937	0.07 P = 0.966	0.17 P = 0.937	0.02 P = 0.994	−0.09 P = 0.937	0.00 P = 1.000	−0.09 P = 0.937	0.04 P = 0.978	−0.09 P = 0.937					
Fe	0.37 P = 0.736	−0.11 P = 0.937	−0.04 P = 0.978	0.09 P = 0.937	−0.09 P = 0.937	−0.48 P = 0.557	−0.32 P = 0.811	−0.22 P = 0.934	−0.26 P = 0.888	−0.29 P = 0.849	−0.02 P = 0.994	0.36 P = 0.736	−0.18 P = 0.937	−0.04 P = 0.978	0.00 P = 1.000	0.18 P = 0.937	−0.39 P = 0.731				
Ferritin	0.20 P = 0.937	−0.04 P = 0.978	−0.02 P = 1.000	−0.29 P = 0.849	−0.20 P = 0.937	0.18 P = 0.937	0.07 P = 0.966	0.42 P = 0.689	0.00 P = 1.000	0.28 P = 0.849	−0.33 P = 0.811	−0.11 P = 0.937	0.20 P = 0.937	0.42 P = 0.689	0.20 P = 0.937	−0.11 P = 0.937	−0.13 P = 0.937	−0.09 P = 0.937			
Se	0.00 P = 1.000	0.25 P = 0.888	0.36 P = 0.736	0.22 P = 0.934	0.22 P = 0.934	0.09 P = 0.937	−0.14 P = 0.937	0.40 P = 0.689	0.12 P = 0.937	0.45 P = 0.689	−0.17 P = 0.937	−0.13 P = 0.937	0.58 P = 0.394	0.22 P = 0.934	0.09 P = 0.937	0.55 P = 0.417	−0.14 P = 0.937	−0.02 P = 0.994	0.18 P = 0.937		
Zn	0.20 P = 0.937	0.36 P = 0.736	0.29 P = 0.849	0.11 P = 0.937	0.02 P = 1.000	0.13 P = 0.937	−0.16 P = 0.937	−0.07 P = 0.978	0.00 P = 1.000	0.24 P = 0.934	−0.33 P = 0.811	0.11 P = 0.937	0.16 P = 0.937	−0.07 P = 0.978	0.16 P = 0.937	0.11 P = 0.937	0.18 P = 0.937	−0.13 P = 0.937	0.42 P = 0.689	0.13 P = 0.937	

1.00
0.50
0.00
-0.50
-1.00

	Age	Height	Weight	grip_R	grip_L	AS	SDS	STAI_S	STAI_T	PSQI	PSS	TEIQue_SF	Adropin	A	B1	Ca	Cu	Fe	Ferritin	Se	Zn
Age																					
Height	0.00 P = 1.000																				
Weight	−0.45 P = 0.380	0.18 P = 0.605																			
grip_R	−0.27 P = 0.607	0.04 P = 0.932	−0.27 P = 0.593										−0.98 P = 0.013								
grip_L	−0.09 P = 0.865	−0.13 P = 0.800	−0.36 P = 0.496	−0.18 P = 0.457																	
AS	0.07 P = 0.898	0.07 P = 0.887	−0.20 P = 0.687	−0.33 P = 0.510	−0.25 P = 0.644																
SDS	0.16 P = 0.762	0.26 P = 0.573	−0.11 P = 0.802	−0.02 P = 0.968	0.16 P = 0.764	−0.20 P = 0.527															
STAI_S	0.45 P = 0.364	0.04 P = 0.929	−0.49 P = 0.295	−0.13 P = 0.793	−0.22 P = 0.674	0.24 P = 0.529	0.20 P = 0.603														
STAI_T	0.20 P = 0.694	0.08 P = 0.870	−0.42 P = 0.377	−0.51 P = 0.291	−0.43 P = 0.415	−0.12 P = 0.685	0.06 P = 0.812	0.36 P = 0.262													
PSQI	0.35 P = 0.487	−0.14 P = 0.792	−0.42 P = 0.423	−0.56 P = 0.283	−0.47 P = 0.360	0.05 P = 0.900	0.44 P = 0.331	0.17 P = 0.674	0.42 P = 0.284												
PSS	0.17 P = 0.753	0.03 P = 0.942	−0.20 P = 0.592	0.07 P = 0.896	0.11 P = 0.820	−0.01 P = 0.980	−0.25 P = 0.552	0.30 P = 0.534	−0.26 P = 0.520	0.12 P = 0.822											
TEIQue_SF	−0.44 P = 0.406	−0.06 P = 0.895	0.25 P = 0.620	0.29 P = 0.553	0.29 P = 0.581	0.04 P = 0.851	0.14 P = 0.628	−0.12 P = 0.691	0.20 P = 0.475	−0.06 P = 0.884	0.19 P = 0.647										
Adropin	0.18 P = 0.726	−0.36 P = 0.496	−0.71 P = 0.151	−0.98 P = 0.013	−0.71 P = 0.143	0.24 P = 0.604	0.43 P = 0.388	0.04 P = 0.924	0.32 P = 0.443	0.32 P = 0.507	0.02 P = 0.963	−0.21 P = 0.647									
A	0.09 P = 0.865	0.67 P = 0.187	0.36 P = 0.501	−0.18 P = 0.739	−0.18 P = 0.739	0.29 P = 0.582	0.02 P = 0.965	−0.04 P = 0.929	0.25 P = 0.639	0.14 P = 0.794	0.03 P = 0.961	−0.25 P = 0.639	−0.09 P = 0.868								
B1	−0.27 P = 0.598	0.36 P = 0.430	0.04 P = 0.929	0.31 P = 0.557	0.13 P = 0.802	−0.11 P = 0.829	0.16 P = 0.757	−0.36 P = 0.496	0.07 P = 0.885	0.05 P = 0.916	0.45 P = 0.304	0.07 P = 0.877	−0.40 P = 0.444	−0.22 P = 0.660							
Ca	−0.16 P = 0.757	0.17 P = 0.708	−0.11 P = 0.794	−0.84 P = 0.082	−0.75 P = 0.133	0.18 P = 0.730	0.14 P = 0.777	−0.02 P = 0.967	0.00 P = 0.998	−0.22 P = 0.684	−0.19 P = 0.693	−0.23 P = 0.663	−0.34 P = 0.489	0.71 P = 0.103	−0.07 P = 0.899						
Cu	−0.25 P = 0.633	−0.11 P = 0.832	−0.02 P = 0.964	−0.16 P = 0.758	0.02 P = 0.969	−0.25 P = 0.623	0.04 P = 0.934	0.07 P = 0.899	−0.23 P = 0.671	−0.40 P = 0.451	−0.09 P = 0.861	−0.04 P = 0.932	−0.11 P = 0.835	0.02 P = 0.965	−0.20 P = 0.706	0.09 P = 0.863					
Fe	−0.64 P = 0.211	0.27 P = 0.607	−0.04 P = 0.933	−0.13 P = 0.800	0.04 P = 0.933	0.43 P = 0.375	0.53 P = 0.311	0.13 P = 0.796	0.39 P = 0.457	0.36 P = 0.496	0.26 P = 0.622	−0.20 P = 0.686	0.13 P = 0.798	−0.22 P = 0.665	0.63 P = 0.166	−0.53 P = 0.303	0.12 P = 0.806				
Ferritin	−0.27 P = 0.606	0.31 P = 0.548	0.44 P = 0.377	0.09 P = 0.859	0.09 P = 0.865	−0.07 P = 0.896	−0.34 P = 0.519	−0.58 P = 0.256	−0.11 P = 0.835	−0.37 P = 0.474	−0.16 P = 0.720	0.16 P = 0.770	−0.09 P = 0.865	0.00 P = 1.000	−0.31 P = 0.557	0.71 P = 0.132	0.38 P = 0.471	−0.31 P = 0.526			
Se	0.26 P = 0.625	−0.43 P = 0.409	−0.79 P = 0.117	−0.43 P = 0.415	−0.38 P = 0.467	0.57 P = 0.190	0.69 P = 0.155	0.44 P = 0.136	0.54 P = 0.207	0.16 P = 0.676	0.67 P = 0.179	−0.60 P = 0.132	−0.29 P = 0.495	0.16 P = 0.738	−0.48 P = 0.352	−0.41 P = 0.370	0.07 P = 0.897	−0.12 P = 0.828	−0.29 P = 0.580		
Zn	−0.14 P = 0.795	−0.31 P = 0.535	−0.22 P = 0.666	−0.58 P = 0.248	−0.58 P = 0.225	−0.11 P = 0.832	−0.02 P = 0.968	0.09 P = 0.868	0.07 P = 0.901	−0.24 P = 0.653	0.26 P = 0.610	−0.16 P = 0.770	0.22 P = 0.653	−0.04 P = 0.933	−0.18 P = 0.738	0.02 P = 0.963	−0.65 P = 0.198	0.27 P = 0.612	−0.40 P = 0.423	−0.16 P = 0.767	

1.00
0.50
0.00
-0.50
-1.00